ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Light pollution is a growing issue. Over the past 25 years, artificial lighting has surged by 49% worldwide. For perspective, the brightness of the…
In the 1950s, doctors Carlton Gajdusek and Vincent Zigas trekked over mountains and across rivers to study a mysterious and fatal neurological disease called…
This year, the world saw new blood tests for Alzheimer’s disease hit the market and two monoclonal antibody drugs for early-stage Alzheimer’s disease approved…
Changes in thinking and memory as we age can occur for a variety of reasons. These changes are not always cause for concern. But…
Imagine being diagnosed with Alzheimer’s in your early 60s and leaving your career, only to find out years later that you had no signs…
This article is part of the Journey to Diagnosis series, produced by Being Patient with support provided by Eli Lilly. In the newest definition…
An international group of researchers is challenging the controversial new definition of Alzheimer’s proposed by a group of researchers convened by the Alzheimer’s Association….
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
Hardly a week goes by when I don’t receive an email or a call from a friend whose parent has just gotten an Alzheimer’s…
Precision medicine is a medical approach that considers a patient’s genes, environment, and lifestyle. In the realm of Alzheimer’s disease, experts are pushing for…
For decades, scientists blamed Alzheimer’s disease on the buildup of beta-amyloid protein plaques in the brain. But most clinical trials for drugs intended to…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…